The ‘non-exclusive rights’ for commercial production of ‘Lumpi-ProVac’ has been granted to IVPB for ten years, an per media reports
The government has notified about signing a pact with the Pune-based Institute of Veterinary Biological Products (IVBP) for developing ‘Lumpi-ProVac’, the indegenous vaccine, to double down on the cure of lumpy skin disease in cattle.
The Haryana-based National Centre for Veterinary Type Culture and ICAR-National Research Centre on Equines in collaboration with Uttar Pradesh-based ICAR-Indian Veterinary Research Institute, had developed this vaccine.
The ‘non-exclusive rights’ for commercial production of ‘Lumpi-ProVac’ has been granted to IVPB for ten years, an per media reports.
The commercial arm of Department of Agriculture Research and Education, Agrinnovate India Ltd, has granted the rights.
After signing the memorandum of understanding (MoU), Union Minister of Fisheries, Animal Husbandry, and Dairying Parshottam Rupala conveyed that IVBP should start large-scale manufacturing of the vaccine without further ado.
Currently, the Goat Pox vaccine is administered for prevention of Lumpy Skin Disease in cattle. Moreover, the signed MoU will ensure large-scale production of Goat Pox vaccine, saving India’s livestock sector in times ahead.
Lumpi-ProVac is used for the prophylactic immunization of animals against lumpy skin disease, with an efficacy period of 1 year. The temperature required to store the vaccine is 4 degrees Celsius. Also, it is necessary that it be shipped on ice and utilised in few hours post reconstitution. According to the statement, the ICAR has filed a patent for the technology.
India discovered Lumpy Skin Disease in 2019, with reporting the first case in Odisha. This was followed by its spread throughout the country’s various states. It led to death of a large number of cattle, especially from the North-West part of the country.
